Receptor Grade IGF-1 LR3 is more biologically active than standard IGF-1 LR3, in-vitro. Resultantly, Receptor Grade IGF-1 LR3 will deliver superior results in comparison to standard IGF-1 LR3.
The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.
IGF-1 is a polypeptide hormone that has many of the same properties as the hormone, insulin. Responsible for long bone growth in children, IGF-1 has anabolic effects on the muscle growth, repair and recovery of adults. Anabolic effects, increasing muscle mass, repair and recovery through muscle hyperplasia. IGF-1 LR-3 is 2-3 times more potent than IGF due to its long half-life.
IGF-1 LR3 boosts muscle mass with great effectiveness by inducing muscle hyperplasia Increases in both the size of muscle cells and the number of muscle cells, (unlike anabolic steroids which just increase the size of muscle cells.) Stimulates the growth of satellite muscle cells, and matures them into new muscle fibres Increases the uptake of Creatine and other supplements Increases the absorption of amino acids and collagen Enhanced to stop deactivation by IGF-1 binding proteins in circulation.
IGF-1 is mostly secreted by the liver due to stimulation by Human Growth Hormone (HGH). Almost every cell in our human body is affected by IGF-1. This includes cells in our muscles, cartilage, bone, kidney, liver, skin, nerves and lungs. IGF-1 is responsible for many of the positive effects of human growth hormone, in particular, muscle building which is caused by the process of hyperplasia (increases in the number of muscle cells, unlike anabolic steroids which just increase the size of muscle cells). This is a unique situation as it means you will also continue to benefit from the effects of IGF-1 even after you stop using it as you will have more muscle cells in your body with which to make more prominent as you continue weight training. An Anabolic Powerhouse, as some refer it to., Long R3 IGF-1 has much more potency than that of IGF-1. Improved to prevent deactivation by IGF-1 binding proteins in circulation. This affects the half-life, increasing it to 20-30 hours as opposed to 20 minutes. IGF-1 LR3 boosts muscle mass with high effectiveness by inducing muscle hyperplasia (increase in some new muscle cells).
IGF-1 LR3 is typically better than HGH. Why? With HGH, IGF levels rise in the liver first, followed by the muscle. IGF-LR3 causes localised IGF levels to soar making its dynamic capabilities up towards 20 hours. IGF-1 stimulates the growth of satellite muscle cells, alongside helps them to mature into new muscle fibres. It also has the potential to increase the uptake of many supplements currently used in bodybuilding. Not only that, IGF-1-LR3 can cause an enhanced recovery of testicle size. The reason IGF-1-LR3 is so very potent has to do with its decreased binding to all known IGF binding proteins which normally inhibit the biological actions of IGF. This is not the case with the extended version of IGF-1.
POTENTIAL NEGATIVE SIDE EFFECTS: Side effects are rare and minimal under the careful supervision of our prescribing Dr. Patients must adhere to the dosage recommendations to ensure the safety and efficacy of peptide supplements provided. This too will ensure that adverse side effects are minimised.
IGF1-LR3 is a modified version of insulin-like growth factor-1. The full name of the peptide is insulin-like growth factor-1 long arginine 3. All IGF-1 derivatives play prominent roles in cell division, cell proliferation, and cell-to-cell communication. Though it has similar effects, IGF-1 LR3 does not adhere to IGF binding proteins as strongly as IGF-1. This results in IGF1-LR3 remaining in the bloodstream 120 times longer than IGF-1. IGF1-LR3 gains its prolonged half-life as a result of its structural changes. The peptide is created by adding 13 amino acids to the N-terminal end of IGF-1 and by converting the glutamic acid at position 3 of IGF-1 to an arginine residue.
Like IGF-1, IGF1-LR3 is a potent stimulus for cell division and proliferation. Its primary effects are on connective tissues like muscle and bone, but it also promotes cell division in liver, kidney, nerve, skin, lung, and blood tissues. IGF-1 is best thought of as a maturation hormone because it not only promotes cell proliferation, but differentiation as well. IGF-1 causes cells to mature, in other words, so that they can carry out their specialized functions.
Unlike IGF-1, IGF1-LR3 remains in the bloodstream for long periods of time. This property makes IGF1-LR3 a much more potent molecule. A dose of IGF1-LR3 provides approximately three times as much cell activation as a similar dose of IGF-1. Note that IGF1-LR3 and all IGF-1 derivatives do not promote cell enlargement (hypertrophy), but rather promote cell division and proliferation (hyperplasia). In the case of muscle, for instance, IGF1-LR3 does not cause muscle cells to get larger, but it does increase total numbers of muscle cells.
IGF1-LR3 boosts fat metabolism in an indirect manner by binding to both the IGF-1R receptor and the insulin receptor. These actions increase glucose uptake from the blood by muscle, nerve, and liver cells. This results in an overall decrease in blood sugar levels, which then triggers adipose tissue as well as the liver to begin breaking down glycogen and triglycerides. Overall, this produces a net decrease in adipose tissue and a net energy consumption (i.e. net catabolism).
Given its role in reducing blood sugar levels, it should come as no surprise that IGF1-LR3 reduces insulin levels as well as the need for exogenous insulin in diabetes. In most cases, this translates into a 10% decrease in insulin requirements to maintain the same blood sugar levels. This fact may help scientists understand how to decrease insulin doses in individuals who have decreased insulin sensitivity and may even offer insight into preventing type 2 diabetes in the first place.
Myostatin (a.k.a. growth differentiation factor 8) is a muscle protein that primarily inhibits the growth and differentiation of muscle cells. While this function is important to prevent unregulated hypertrophy and ensure proper healing following injury, there are times when inhibiting myostatin could be of benefit. The ability to stop myostatin from functioning could be useful in conditions like Duchenne muscle dystrophy (DMD) or in people who suffer muscle loss during prolonged immobility. In these cases, inhibiting this natural enzyme could help to slow muscle breakdown, maintain strength, and stave off morbidity.
â€‹In mouse models of DMD, it has been found that IGF1-LR3 and other IGF-1 derivatives are capable of counteracting the negative effects of myostatin to protect muscle cells and prevent apoptosis. IGF1-LR3, thanks to its long half-life, is highly effective in counteracting myostatin and appears to work by activating a muscle protein called MyoD, . MyoD is the protein normally activated by exercise (e.g. weight lifting) or tissue damage and is responsible for muscle hypertrophy.
IGF1-LR3 promotes tissue repair and maintenance throughout the body, making it a protective molecule against cell damage and the effects of aging. Research in cows and pigs indicates that IGF1-LR3 administration may be an effective solution for offsetting the effects of cellular aging. Ongoing research in mice seeks to determine if IGF1-LR3 might be useful in preventing progression of a wide range of conditions such as dementia, muscle atrophy, and kidney disease. This research reveals that IGF-1 administration can prolong life and reduce disability, , [5, p. 1].
Glucocorticoids, secreted primarily by the adrenal glands, are important clinical drugs used to control pain and reduce inflammation in autoimmune diseases, neurological injury, cancer, and more. Unfortunately, glucocorticoids have a number of undesirable side effects such as muscle wasting, fat gain, and deterioration of bone density. There is some interest in using IGF1-LR3 to reduce the side effects of glucocorticoids and thus allow for more effective therapy.
IGF1-LR3 exhibits minimal to moderate side effects, low oral and excellent subcutaneous bioavailability in mice. Per kg dosage in mice does not scale to humans. IGF1-LR3 for sale at Peptide Sciences is limited to educational and scientific research only, not for human consumption. Only buy IGF1-LR3 if you are a licensed researcher.â€‹
The above literature was researched, edited and organized by Dr. E. Logan, M.D. Dr. E. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.
Dr. Anastasios Philippou, Ph.D. focused on Experimental Physiology at the National & Kapodistrian University of Athens Medical School. He is now a National Center Manager and Assistant Professor, however his extensive studying and documented research pertaining to the effects of muscle regeneration, the role of IGF-1 in skeletal muscle physiology, the expression of IGF-1 isoforms after exercise induced muscle damage in humans, characterization of the MGF E peptide actions in vitro, and epigenetic regulation on gene expression induced by physical exercise are most impressive.
Dr. Anastasios Philippou, Ph.D. is being referenced as one of the leading scientists involved in the research and development of IGF1-LR3. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Sciences and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. Dr. Anastasios Philippou, Ph.D. is listed in  and  under the referenced citations. 781b155fdc